In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

Health News // 4 hours ago Medicaid covers GLP-1 weight-loss drugs in just 13 states Only 13 states currently allow Medicaid ...

Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite, slow digestion, help stabilize blood sugar levels and impact ...

The drug semaglutide is already proving incredibly effective in tackling diabetes (under the brand name Ozempic) and weight ...

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...